SVRA

-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community -- Savara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at CHEST 2026 in Phoenix, Arizona, October 18–21. Oral Presentation Title: Long-Term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Trial Open-Label Treatment Period Session ID: 4175, ILD Treat

Analyst initiated coverage of Savara with a rating of Overweight and set a new price target of $12.00

4 - Savara Inc (0001160308) (Issuer)

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026."Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may normalize the underlying pathobiology," said Bruce C. Trapnell, M.D., Professor of Medicine and

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material

S-8 - Savara Inc (0001160308) (Filer)

10-Q - Savara Inc (0001160308) (Filer)

MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026 MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041 ~$173M in Cash and Short-Term Investments as of June 30, 2026, Plus up to ~$150M of Non-Dilutive Capital Upon FDA Approval of MOLBREEVI, Positions the Company Well for Launch Savara Inc. (NASDAQ:SVRA) (the Company), a clinica

-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has also granted

4 - Savara Inc (0001160308) (Issuer)

Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease experience, including executive and Board roles at Savara Inc. (NASDAQ:SVRA), Soleno Therapeutics (NASDAQ:SLNO), Strongbridge Biopharma (NASDAQ:SBBP) and Insmed Incorporated (NASDAQ:INSM) WAYNE, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which th

4 - Savara Inc (0001160308) (Issuer)

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company's common stock, restricted stock units (RSUs) covering 42,500 shares of the Company's common stock, and performance stock units (PSUs) covering 8,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan

8-K - Savara Inc (0001160308) (Filer)

-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, M.B.A., the Company's Chief Operating Officer, will assume the additional role of Chief Financial Officer, whi

Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: "Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)," presented by Y. Inoue, M.D.; sponsored by Savara Inc. Presented serum biomarker data from IMPALA-

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 -- -- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension -- -- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period -- -- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is

-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the data presented. Oral Presentation, Abstract 9296: "Molgramostim Improves Exercise Distance and Duration in Patients with Au

10-Q - Savara Inc (0001160308) (Filer)

Achieved Regulatory Milestones for the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP): Biologics License Application (BLA) Filed by the U.S. Food & Drug Administration (FDA), Prescription Drug User Fee Act (PDUFA) Target Action Date is November 22, 2026 Marketing Authorization Applications (MAAs) Validated by the European Medicines Agency (EMA) and the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) with Decisions Expected in Q1 2027 and Q4 2026, respectively Announced New Data from the Phase 3 IMPALA-2 Clinical Trial Will be Presented at the American Thoracic Society (ATS) International Conference in May, Including D

Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulo

DEFA14A - Savara Inc (0001160308) (Filer)

DEF 14A - Savara Inc (0001160308) (Filer)

Oppenheimer resumed coverage of Savara with a rating of Outperform and set a new price target of $11.00 from $9.00 previously